gefitinib has been researched along with raltitrexed in 6 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (raltitrexed) | Trials (raltitrexed) | Recent Studies (post-2010) (raltitrexed) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 580 | 143 | 121 |
| Protein | Taxonomy | gefitinib (IC50) | raltitrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 7.0667 | |
| Dihydrofolate reductase | Homo sapiens (human) | 1.8578 | |
| Thymidylate synthase | Lacticaseibacillus casei | 8.2667 | |
| Thymidylate synthase | Homo sapiens (human) | 1.208 | |
| Thymidylate synthase | Mus musculus (house mouse) | 0.67 | |
| Thymidylate synthase | Escherichia coli K-12 | 2.32 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.32 | |
| Folate receptor beta | Homo sapiens (human) | 0.384 | |
| Folate receptor alpha | Homo sapiens (human) | 0.015 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.26 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0063 | |
| Thymidylate synthase | Rattus norvegicus (Norway rat) | 0.9 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.7956 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bansal, R; Malhotra, A | 1 |
| Bovio, H; de Sande González, L; García-Foncillas, J; García-Girón, C; García-López, JL; Lacave, AJ; Peláez, I; Reboredo, M; Valladares, M; Viéitez, JM | 1 |
| Cassidy, J; Hochster, H | 1 |
2 review(s) available for gefitinib and raltitrexed
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
1 trial(s) available for gefitinib and raltitrexed
| Article | Year |
|---|---|
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Demography; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Young Adult | 2011 |
3 other study(ies) available for gefitinib and raltitrexed
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |